Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting Ligand Unit through a Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.

Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting Ligand Unit through a Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.

The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.

##STR00001##

The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.

##STR00001##

The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.

##STR00001##

The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.

##STR00001##

Provided are methods of producing cobalt-based nanoparticles (Co.sub.xB.sub.y NPs) of a pre-selected diameter. The methods include reducing Co.sup.2+ ions with a sodium borohydride (NaBH.sub.4) solution having a selected ratio of tetrahydroxyborate (B(OH).sub.4.sup.) to tetrahydroborate (BH.sub.4.sup.) based on the pre-selected diameter, where the ratio of B(OH).sub.4.sup. to BH.sub.4.sup. is positively correlated with the pre-selected diameter. Also provided are methods of using the Co.sub.xB.sub.y NPs to produce hollow metal nanospheres (HMNs). Methods of producing Co.sub.xB.sub.y NP core/metal shell structures are also provided, such methods including combining in an anaerobic galvanic exchange reaction a deaerated solution including Co.sub.xB.sub.y NP scaffolds and a deaerated solution including a metal. Also provided are methods of producing HMNs from the Co.sub.xB.sub.y NP core/metal shell structures. Compositions and kits that find use in practicing the methods of the present disclosure and using HMNs produced in accordance with the methods of the present disclosure, are also provided.

Provided are methods of producing cobalt-based nanoparticles (Co.sub.xB.sub.y NPs) of a pre-selected diameter. The methods include reducing Co.sup.2+ ions with a sodium borohydride (NaBH.sub.4) solution having a selected ratio of tetrahydroxyborate (B(OH).sub.4.sup.) to tetrahydroborate (BH.sub.4.sup.) based on the pre-selected diameter, where the ratio of B(OH).sub.4.sup. to BH.sub.4.sup. is positively correlated with the pre-selected diameter. Also provided are methods of using the Co.sub.xB.sub.y NPs to produce hollow metal nanospheres (HMNs). Methods of producing Co.sub.xB.sub.y NP core/metal shell structures are also provided, such methods including combining in an anaerobic galvanic exchange reaction a deaerated solution including Co.sub.xB.sub.y NP scaffolds and a deaerated solution including a metal. Also provided are methods of producing HMNs from the Co.sub.xB.sub.y NP core/metal shell structures. Compositions and kits that find use in practicing the methods of the present disclosure and using HMNs produced in accordance with the methods of the present disclosure, are also provided.

The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg.sub.9-Bradykinin and des-Arg.sub.10-Kallidin-like peptide.

The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg.sub.9-Bradykinin and des-Arg.sub.10-Kallidin-like peptide.